世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

医薬品、バイオテクノロジー、診断薬における共同開発提携条件と契約の世界市場インサイト、2029年までの予測


Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Insights, Forecast to 2029

共同開発パートナーとの提携により、当事者は価 値を確保しリスクを軽減することができるが、製 品が市場に出た場合の潜在的なアップサイドの一部を 保持することができる。ライセンサーがプロジェク トを商業化... もっと見る

　

　

出版社 出版年月 電子版価格 言語
QYResearch
QYリサーチ 		2023年12月5日 US$4,900
シングルユーザライセンス
ライセンス・価格情報・注文方法はこちら 		英語

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。
日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


　

サマリー

共同開発パートナーとの提携により、当事者は価 値を確保しリスクを軽減することができるが、製 品が市場に出た場合の潜在的なアップサイドの一部を 保持することができる。ライセンサーがプロジェク トを商業化しなかった場合、ライセンシー・パート ナーまたは別のパートナーに、より早い段階のライセ ンス契約よりも高い金額で権利を売却することができ る。

市場分析と洞察製薬、バイオテクノロジー、診断薬市場における世界の共同開発提携条件と契約
医薬品、バイオテクノロジー、診断薬における共同開発提携条件と契約の世界市場は、2022年の100万米ドルに比べ、2023年にはプラス成長で100万米ドルに達すると予測される。川下産業からの需要の増加を背景に、医薬品、バイオテクノロジー、診断薬業界における共同開発提携条件と契約は、2029年には百万米ドルに達すると評価されている。2023年から2029年までのCAGRは％である。

世界の医薬品市場は2022年に1,475億米ドルとなり、今後6年間のCAGRは5％で成長する。医薬品市場には、化学医薬品と生物学的製剤が含まれる。生物製剤は2022年に3810億ドルになると予想されている。これに対し、化学医薬品市場は2018年の1,050億米ドルから2022年には1,090億米ドルに増加すると推定されている。医薬品市場の要因としては、医療需要の増加、技術の進歩、慢性疾患の有病率の上昇、医薬品製造分野の開発に対する民間＆政府機関からの資金提供の増加、医薬品の研究開発活動の活発化などが挙げられる。しかし、厳しい規制、研究開発費の高騰、特許切れといった課題にも直面している。企業は、市場での競争力を維持し、必要とする患者に確実に製品を届けるために、継続的に技術革新を行い、こうした課題に適応していく必要がある。さらに、COVID-19の流行はワクチン開発とサプライチェーン・マネジメントの重要性を浮き彫りにし、製薬企業が新たな公衆衛生のニーズに機敏に対応する必要性をさらに強調している。

レポートの対象
本レポートは、2018年から2029年までの世界の製薬・バイオテクノロジー・診断薬における共同開発提携条件と契約市場の概要を紹介し、読者が世界の製薬・バイオテクノロジー・診断薬における共同開発提携条件と契約市場を多角的に包括的に理解することを目的としています。2018年から2029年までの地域別収益、2018年から2023年までの企業の収益と粗利益率などの項目を分析しています。さらに、2018年から2029年までの各地域の製品タイプおよびアプリケーションの収益も取り上げています。

レポートに掲載されている企業、タイプ、アプリケーション、地域
企業別
1STバイオセラピューティクス
3Bファーマシューティカルズ
3Dマイクロマック
3DMed
3Dシステムズ
10X ジェノミクス
A*STAR 科学技術庁
科学技術研究庁
A*STARマイクロエレクトロニクス研究所（IME）
A2Aファーマシューティカルズ
アッヴィ
アブセラ
ABLバイオ
アブプロ
軍医科学アカデミー（中国）
アクセリックス
アコードヘルスケア
アキュジェノミクス
ACEAバイオサイエンシズ
ACイミューン
アコースティック・メドシステムズ
アダプティミューン
アドゥロ・バイオテック
アドバクシス
アドベンタス・ベンチャーズ
エアロラーゼ
タイプ別セグメント
資産購入
譲渡
共同開発
共同マーケティング
共同販促
共同研究開発
契約サービス
CRADA
クロスライセンス
その他
用途別セグメント
産業分野
治療分野
技術タイプ
契約内容
財務条件
開発段階
その他
地域別
北米
米国
カナダ
欧州
ドイツ
フランス
英国
イタリア
ロシア
北欧諸国
その他の欧州諸国
中国
アジア（中国を除く）
日本
韓国
中国 台湾
東南アジア
インド
ラテンアメリカ、中東、アフリカ
ブラジル
メキシコ
トルコ
イスラエル
GCC諸国

章の概要
第1章：製品の定義、タイプ、用途の紹介
第2章 2018年から2029年までの地域別収益分析
第3章：製品名企業の競争環境、収益、市場シェア、業界ランキング、最新の開発計画、合併・買収情報などの詳細分析
第4章 2018年から2029年までの世界のタイプ別製品収益分析
第5章 世界の2018年から2029年までの用途別製品収益分析
第6章：2018年から2029年までの米国・カナダのタイプ別・用途別製品収益分析2018年から2029年までの米国＆カナダにおける各国の製品収益分析
第7章：欧州における2018年から2029年までのタイプ別および用途別製品収益分析。2018年から2029年までの欧州における各国の製品収益分析
第8章：2018年から2029年までの中国のタイプ別および用途別製品収益分析。2018年から2029年までの中国の製品収益分析
第9章：2018年から2029年までのアジア（中国を除く）のタイプ別・用途別製品収益分析。2018年から2029年までのアジア（中国を除く）の各国の製品収益分析
第10章：2018年から2029年までの中東、アフリカ、ラテンアメリカにおけるタイプ別および用途別の製品収益分析。2018年から2029年までの中東、アフリカ、ラテンアメリカにおける各国の製品収益分析。
第11章：企業概要：企業の基本情報、主要事業、製薬・バイオテクノロジー・診断薬紹介における共同開発提携条件と契約などを網羅。2018年から2023年までの製薬、バイオテクノロジー、診断薬における共同開発提携条件と契約 各社の売上高とグロスマージン
第12章：製薬、バイオテクノロジー、診断薬における共同開発提携条件と契約に関するQYResearchの結論
第13章：QYResearchが採用した方法論とデータソース


ページTOPに戻る


目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Asset purchase
1.2.3 Assignment
1.2.4 Co-development
1.2.5 Co-market
1.2.6 Co-promotion
1.2.7 Collaborative R&D
1.2.8 Contract service
1.2.9 CRADA
1.2.10 Cross-licensing
1.2.11 Others
1.3 Market by Application
1.3.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Industry sector
1.3.3 Therapy areas
1.3.4 Technology type
1.3.5 Deal components
1.3.6 Financial terms
1.3.7 Stage of development
1.3.8 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Perspective (2018-2029)
2.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Growth Trends by Region
2.2.1 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Historic Market Size by Region (2018-2023)
2.2.3 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecasted Market Size by Region (2024-2029)
2.3 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Dynamics
2.3.1 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Industry Trends
2.3.2 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Drivers
2.3.3 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Challenges
2.3.4 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics by Players
3.1.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue by Players (2018-2023)
3.1.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Market Share by Players (2018-2023)
3.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Concentration Ratio
3.4.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue in 2022
3.5 Global Key Players of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Head office and Area Served
3.6 Global Key Players of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, Product and Application
3.7 Global Key Players of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Breakdown Data by Type
4.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Historic Market Size by Type (2018-2023)
4.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecasted Market Size by Type (2024-2029)
5 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Breakdown Data by Application
5.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Historic Market Size by Application (2018-2023)
5.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2018-2029)
6.2 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type
6.2.1 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2018-2023)
6.2.2 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2024-2029)
6.2.3 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Type (2018-2029)
6.3 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application
6.3.1 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2018-2023)
6.3.2 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2024-2029)
6.3.3 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Application (2018-2029)
6.4 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country
6.4.1 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2018-2023)
6.4.3 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2024-2029)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2018-2029)
7.2 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type
7.2.1 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2018-2023)
7.2.2 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2024-2029)
7.2.3 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Type (2018-2029)
7.3 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application
7.3.1 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2018-2023)
7.3.2 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2024-2029)
7.3.3 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Application (2018-2029)
7.4 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country
7.4.1 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2018-2023)
7.4.3 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2018-2029)
8.2 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type
8.2.1 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2018-2023)
8.2.2 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2024-2029)
8.2.3 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Type (2018-2029)
8.3 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application
8.3.1 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2018-2023)
8.3.2 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2024-2029)
8.3.3 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2018-2029)
9.2 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type
9.2.1 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2018-2023)
9.2.2 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2024-2029)
9.2.3 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Type (2018-2029)
9.3 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application
9.3.1 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2018-2023)
9.3.2 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2024-2029)
9.3.3 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Application (2018-2029)
9.4 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region
9.4.1 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region (2018-2023)
9.4.3 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type
10.2.1 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application
10.3.1 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country
10.4.1 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 1ST Biotherapeutics
11.1.1 1ST Biotherapeutics Company Details
11.1.2 1ST Biotherapeutics Business Overview
11.1.3 1ST Biotherapeutics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.1.4 1ST Biotherapeutics Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.1.5 1ST Biotherapeutics Recent Developments
11.2 3B Pharmaceuticals
11.2.1 3B Pharmaceuticals Company Details
11.2.2 3B Pharmaceuticals Business Overview
11.2.3 3B Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.2.4 3B Pharmaceuticals Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.2.5 3B Pharmaceuticals Recent Developments
11.3 3D-Micromac
11.3.1 3D-Micromac Company Details
11.3.2 3D-Micromac Business Overview
11.3.3 3D-Micromac Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.3.4 3D-Micromac Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.3.5 3D-Micromac Recent Developments
11.4 3DMed
11.4.1 3DMed Company Details
11.4.2 3DMed Business Overview
11.4.3 3DMed Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.4.4 3DMed Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.4.5 3DMed Recent Developments
11.5 3D Systems
11.5.1 3D Systems Company Details
11.5.2 3D Systems Business Overview
11.5.3 3D Systems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.5.4 3D Systems Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.5.5 3D Systems Recent Developments
11.6 10X Genomics
11.6.1 10X Genomics Company Details
11.6.2 10X Genomics Business Overview
11.6.3 10X Genomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.6.4 10X Genomics Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.6.5 10X Genomics Recent Developments
11.7 A*STAR Agency for Science
11.7.1 A*STAR Agency for Science Company Details
11.7.2 A*STAR Agency for Science Business Overview
11.7.3 A*STAR Agency for Science Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.7.4 A*STAR Agency for Science Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.7.5 A*STAR Agency for Science Recent Developments
11.8 Technology and Research
11.8.1 Technology and Research Company Details
11.8.2 Technology and Research Business Overview
11.8.3 Technology and Research Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.8.4 Technology and Research Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.8.5 Technology and Research Recent Developments
11.9 A*STAR Institute of Microelectronics (IME)
11.9.1 A*STAR Institute of Microelectronics (IME) Company Details
11.9.2 A*STAR Institute of Microelectronics (IME) Business Overview
11.9.3 A*STAR Institute of Microelectronics (IME) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.9.4 A*STAR Institute of Microelectronics (IME) Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.9.5 A*STAR Institute of Microelectronics (IME) Recent Developments
11.10 A2A Pharmaceuticals
11.10.1 A2A Pharmaceuticals Company Details
11.10.2 A2A Pharmaceuticals Business Overview
11.10.3 A2A Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.10.4 A2A Pharmaceuticals Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.10.5 A2A Pharmaceuticals Recent Developments
11.11 Abbvie
11.11.1 Abbvie Company Details
11.11.2 Abbvie Business Overview
11.11.3 Abbvie Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.11.4 Abbvie Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.11.5 Abbvie Recent Developments
11.12 AbCellera
11.12.1 AbCellera Company Details
11.12.2 AbCellera Business Overview
11.12.3 AbCellera Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.12.4 AbCellera Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.12.5 AbCellera Recent Developments
11.13 ABL Bio
11.13.1 ABL Bio Company Details
11.13.2 ABL Bio Business Overview
11.13.3 ABL Bio Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.13.4 ABL Bio Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.13.5 ABL Bio Recent Developments
11.14 Abpro
11.14.1 Abpro Company Details
11.14.2 Abpro Business Overview
11.14.3 Abpro Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.14.4 Abpro Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.14.5 Abpro Recent Developments
11.15 Academy of Military Medical Sciences (China)
11.15.1 Academy of Military Medical Sciences (China) Company Details
11.15.2 Academy of Military Medical Sciences (China) Business Overview
11.15.3 Academy of Military Medical Sciences (China) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.15.4 Academy of Military Medical Sciences (China) Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.15.5 Academy of Military Medical Sciences (China) Recent Developments
11.16 Accellix
11.16.1 Accellix Company Details
11.16.2 Accellix Business Overview
11.16.3 Accellix Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.16.4 Accellix Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.16.5 Accellix Recent Developments
11.17 Accord Healthcare
11.17.1 Accord Healthcare Company Details
11.17.2 Accord Healthcare Business Overview
11.17.3 Accord Healthcare Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.17.4 Accord Healthcare Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.17.5 Accord Healthcare Recent Developments
11.18 AccuGenomics
11.18.1 AccuGenomics Company Details
11.18.2 AccuGenomics Business Overview
11.18.3 AccuGenomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.18.4 AccuGenomics Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.18.5 AccuGenomics Recent Developments
11.19 ACEA Biosciences
11.19.1 ACEA Biosciences Company Details
11.19.2 ACEA Biosciences Business Overview
11.19.3 ACEA Biosciences Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.19.4 ACEA Biosciences Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.19.5 ACEA Biosciences Recent Developments
11.20 AC Immune
11.20.1 AC Immune Company Details
11.20.2 AC Immune Business Overview
11.20.3 AC Immune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.20.4 AC Immune Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.20.5 AC Immune Recent Developments
11.21 Acoustic MedSystems
11.21.1 Acoustic MedSystems Company Details
11.21.2 Acoustic MedSystems Business Overview
11.21.3 Acoustic MedSystems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.21.4 Acoustic MedSystems Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.21.5 Acoustic MedSystems Recent Developments
11.22 Adaptimmune
11.22.1 Adaptimmune Company Details
11.22.2 Adaptimmune Business Overview
11.22.3 Adaptimmune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.22.4 Adaptimmune Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.22.5 Adaptimmune Recent Developments
11.23 Aduro BioTech
11.23.1 Aduro BioTech Company Details
11.23.2 Aduro BioTech Business Overview
11.23.3 Aduro BioTech Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.23.4 Aduro BioTech Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.23.5 Aduro BioTech Recent Developments
11.24 Advaxis
11.24.1 Advaxis Company Details
11.24.2 Advaxis Business Overview
11.24.3 Advaxis Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.24.4 Advaxis Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.24.5 Advaxis Recent Developments
11.25 Adventus Ventures
11.25.1 Adventus Ventures Company Details
11.25.2 Adventus Ventures Business Overview
11.25.3 Adventus Ventures Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.25.4 Adventus Ventures Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.25.5 Adventus Ventures Recent Developments
11.26 Aerolase
11.26.1 Aerolase Company Details
11.26.2 Aerolase Business Overview
11.26.3 Aerolase Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.26.4 Aerolase Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.26.5 Aerolase Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

　

ページTOPに戻る


　

Summary

Co-development partnering allow the parties to securitize value and reduce risk, but keep a part of the potential upside should the product reach the market. Event if the licensor does not commercialize the project they can either sell those rights to the licensee partner or another partner for an amount higher than would have been achieved at an earlier stage licensing deal.

Market Analysis and Insights: Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market
Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics market is expected to reach to US$ million in 2023, with a positive growth of %, compared with US$ million in 2022. Backed with the increasing demand from downstream industries, Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics industry is evaluated to reach US$ million in 2029. The CAGR will be % during 2023 to 2029.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Covers:
This report presents an overview of global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2023 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.

Companies, Type, Application and Regions Listed in the Report:
By Company
1ST Biotherapeutics
3B Pharmaceuticals
3D-Micromac
3DMed
3D Systems
10X Genomics
A*STAR Agency for Science
Technology and Research
A*STAR Institute of Microelectronics (IME)
A2A Pharmaceuticals
Abbvie
AbCellera
ABL Bio
Abpro
Academy of Military Medical Sciences (China)
Accellix
Accord Healthcare
AccuGenomics
ACEA Biosciences
AC Immune
Acoustic MedSystems
Adaptimmune
Aduro BioTech
Advaxis
Adventus Ventures
Aerolase
Segment by Type
Asset purchase
Assignment
Co-development
Co-market
Co-promotion
Collaborative R&D
Contract service
CRADA
Cross-licensing
Others
Segment by Application
Industry sector
Therapy areas
Technology type
Deal components
Financial terms
Stage of development
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline
Chapter 1: Product definition, type and application introduction
Chapter 2: Regional revenue analysis from 2018 to 2029
Chapter 3: Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Product revenue analysis by type from 2018 to 2029 globally
Chapter 5: Product revenue analysis by application from 2018 to 2029 globally
Chapter 6: Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7: Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8: Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9: Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10: Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11: Companies’ outline, covering company’s basic information, major business, Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics introduction, etc. Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue and Gross Margin of each company from 2018 to 2023
Chapter 12: QYResearch’s Conclusions of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
Chapter 13: Methodology and Data Sources adopted by QYResearch



ページTOPに戻る


Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Asset purchase
1.2.3 Assignment
1.2.4 Co-development
1.2.5 Co-market
1.2.6 Co-promotion
1.2.7 Collaborative R&D
1.2.8 Contract service
1.2.9 CRADA
1.2.10 Cross-licensing
1.2.11 Others
1.3 Market by Application
1.3.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Industry sector
1.3.3 Therapy areas
1.3.4 Technology type
1.3.5 Deal components
1.3.6 Financial terms
1.3.7 Stage of development
1.3.8 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Perspective (2018-2029)
2.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Growth Trends by Region
2.2.1 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Historic Market Size by Region (2018-2023)
2.2.3 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecasted Market Size by Region (2024-2029)
2.3 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Dynamics
2.3.1 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Industry Trends
2.3.2 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Drivers
2.3.3 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Challenges
2.3.4 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics by Players
3.1.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue by Players (2018-2023)
3.1.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Market Share by Players (2018-2023)
3.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Concentration Ratio
3.4.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue in 2022
3.5 Global Key Players of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Head office and Area Served
3.6 Global Key Players of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, Product and Application
3.7 Global Key Players of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Breakdown Data by Type
4.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Historic Market Size by Type (2018-2023)
4.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecasted Market Size by Type (2024-2029)
5 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Breakdown Data by Application
5.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Historic Market Size by Application (2018-2023)
5.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2018-2029)
6.2 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type
6.2.1 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2018-2023)
6.2.2 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2024-2029)
6.2.3 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Type (2018-2029)
6.3 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application
6.3.1 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2018-2023)
6.3.2 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2024-2029)
6.3.3 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Application (2018-2029)
6.4 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country
6.4.1 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2018-2023)
6.4.3 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2024-2029)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2018-2029)
7.2 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type
7.2.1 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2018-2023)
7.2.2 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2024-2029)
7.2.3 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Type (2018-2029)
7.3 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application
7.3.1 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2018-2023)
7.3.2 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2024-2029)
7.3.3 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Application (2018-2029)
7.4 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country
7.4.1 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2018-2023)
7.4.3 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2018-2029)
8.2 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type
8.2.1 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2018-2023)
8.2.2 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2024-2029)
8.2.3 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Type (2018-2029)
8.3 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application
8.3.1 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2018-2023)
8.3.2 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2024-2029)
8.3.3 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2018-2029)
9.2 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type
9.2.1 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2018-2023)
9.2.2 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2024-2029)
9.2.3 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Type (2018-2029)
9.3 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application
9.3.1 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2018-2023)
9.3.2 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2024-2029)
9.3.3 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Application (2018-2029)
9.4 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region
9.4.1 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region (2018-2023)
9.4.3 Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type
10.2.1 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application
10.3.1 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country
10.4.1 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 1ST Biotherapeutics
11.1.1 1ST Biotherapeutics Company Details
11.1.2 1ST Biotherapeutics Business Overview
11.1.3 1ST Biotherapeutics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.1.4 1ST Biotherapeutics Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.1.5 1ST Biotherapeutics Recent Developments
11.2 3B Pharmaceuticals
11.2.1 3B Pharmaceuticals Company Details
11.2.2 3B Pharmaceuticals Business Overview
11.2.3 3B Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.2.4 3B Pharmaceuticals Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.2.5 3B Pharmaceuticals Recent Developments
11.3 3D-Micromac
11.3.1 3D-Micromac Company Details
11.3.2 3D-Micromac Business Overview
11.3.3 3D-Micromac Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.3.4 3D-Micromac Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.3.5 3D-Micromac Recent Developments
11.4 3DMed
11.4.1 3DMed Company Details
11.4.2 3DMed Business Overview
11.4.3 3DMed Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.4.4 3DMed Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.4.5 3DMed Recent Developments
11.5 3D Systems
11.5.1 3D Systems Company Details
11.5.2 3D Systems Business Overview
11.5.3 3D Systems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.5.4 3D Systems Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.5.5 3D Systems Recent Developments
11.6 10X Genomics
11.6.1 10X Genomics Company Details
11.6.2 10X Genomics Business Overview
11.6.3 10X Genomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.6.4 10X Genomics Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.6.5 10X Genomics Recent Developments
11.7 A*STAR Agency for Science
11.7.1 A*STAR Agency for Science Company Details
11.7.2 A*STAR Agency for Science Business Overview
11.7.3 A*STAR Agency for Science Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.7.4 A*STAR Agency for Science Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.7.5 A*STAR Agency for Science Recent Developments
11.8 Technology and Research
11.8.1 Technology and Research Company Details
11.8.2 Technology and Research Business Overview
11.8.3 Technology and Research Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.8.4 Technology and Research Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.8.5 Technology and Research Recent Developments
11.9 A*STAR Institute of Microelectronics (IME)
11.9.1 A*STAR Institute of Microelectronics (IME) Company Details
11.9.2 A*STAR Institute of Microelectronics (IME) Business Overview
11.9.3 A*STAR Institute of Microelectronics (IME) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.9.4 A*STAR Institute of Microelectronics (IME) Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.9.5 A*STAR Institute of Microelectronics (IME) Recent Developments
11.10 A2A Pharmaceuticals
11.10.1 A2A Pharmaceuticals Company Details
11.10.2 A2A Pharmaceuticals Business Overview
11.10.3 A2A Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.10.4 A2A Pharmaceuticals Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.10.5 A2A Pharmaceuticals Recent Developments
11.11 Abbvie
11.11.1 Abbvie Company Details
11.11.2 Abbvie Business Overview
11.11.3 Abbvie Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.11.4 Abbvie Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.11.5 Abbvie Recent Developments
11.12 AbCellera
11.12.1 AbCellera Company Details
11.12.2 AbCellera Business Overview
11.12.3 AbCellera Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.12.4 AbCellera Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.12.5 AbCellera Recent Developments
11.13 ABL Bio
11.13.1 ABL Bio Company Details
11.13.2 ABL Bio Business Overview
11.13.3 ABL Bio Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.13.4 ABL Bio Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.13.5 ABL Bio Recent Developments
11.14 Abpro
11.14.1 Abpro Company Details
11.14.2 Abpro Business Overview
11.14.3 Abpro Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.14.4 Abpro Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.14.5 Abpro Recent Developments
11.15 Academy of Military Medical Sciences (China)
11.15.1 Academy of Military Medical Sciences (China) Company Details
11.15.2 Academy of Military Medical Sciences (China) Business Overview
11.15.3 Academy of Military Medical Sciences (China) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.15.4 Academy of Military Medical Sciences (China) Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.15.5 Academy of Military Medical Sciences (China) Recent Developments
11.16 Accellix
11.16.1 Accellix Company Details
11.16.2 Accellix Business Overview
11.16.3 Accellix Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.16.4 Accellix Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.16.5 Accellix Recent Developments
11.17 Accord Healthcare
11.17.1 Accord Healthcare Company Details
11.17.2 Accord Healthcare Business Overview
11.17.3 Accord Healthcare Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.17.4 Accord Healthcare Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.17.5 Accord Healthcare Recent Developments
11.18 AccuGenomics
11.18.1 AccuGenomics Company Details
11.18.2 AccuGenomics Business Overview
11.18.3 AccuGenomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.18.4 AccuGenomics Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.18.5 AccuGenomics Recent Developments
11.19 ACEA Biosciences
11.19.1 ACEA Biosciences Company Details
11.19.2 ACEA Biosciences Business Overview
11.19.3 ACEA Biosciences Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.19.4 ACEA Biosciences Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.19.5 ACEA Biosciences Recent Developments
11.20 AC Immune
11.20.1 AC Immune Company Details
11.20.2 AC Immune Business Overview
11.20.3 AC Immune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.20.4 AC Immune Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.20.5 AC Immune Recent Developments
11.21 Acoustic MedSystems
11.21.1 Acoustic MedSystems Company Details
11.21.2 Acoustic MedSystems Business Overview
11.21.3 Acoustic MedSystems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.21.4 Acoustic MedSystems Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.21.5 Acoustic MedSystems Recent Developments
11.22 Adaptimmune
11.22.1 Adaptimmune Company Details
11.22.2 Adaptimmune Business Overview
11.22.3 Adaptimmune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.22.4 Adaptimmune Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.22.5 Adaptimmune Recent Developments
11.23 Aduro BioTech
11.23.1 Aduro BioTech Company Details
11.23.2 Aduro BioTech Business Overview
11.23.3 Aduro BioTech Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.23.4 Aduro BioTech Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.23.5 Aduro BioTech Recent Developments
11.24 Advaxis
11.24.1 Advaxis Company Details
11.24.2 Advaxis Business Overview
11.24.3 Advaxis Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.24.4 Advaxis Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.24.5 Advaxis Recent Developments
11.25 Adventus Ventures
11.25.1 Adventus Ventures Company Details
11.25.2 Adventus Ventures Business Overview
11.25.3 Adventus Ventures Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.25.4 Adventus Ventures Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.25.5 Adventus Ventures Recent Developments
11.26 Aerolase
11.26.1 Aerolase Company Details
11.26.2 Aerolase Business Overview
11.26.3 Aerolase Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.26.4 Aerolase Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2018-2023)
11.26.5 Aerolase Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（診断薬）の最新刊レポート

QYResearch 社の最新刊レポート

本レポートと同じKEY WORD（diagnostics）の最新刊レポート


よくあるご質問


QYResearch社はどのような調査会社ですか?


QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。   QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/10/04　10:27

147.72 円

163.39 円

196.69 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.